Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
Author:
Publisher
Medknow
Subject
Developmental Neuroscience
Reference12 articles.
1. Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O’Gorman J, Haeberlein SB, et al. (2021) Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27:1451-1457.
2. Höglinger G, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H; Arise Investigators (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet Neurol 20:182-192.
3. Horie K, Barthélemy NR, Sato C, Bateman RJ (2021) CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain 144:515-527.
4. Kent SA, Spires-Jones TL, Durrant CS (2020) The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol 140:417-447.
5. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early Alzheimer’s disease. N Engl J Med 384:1691-1704.
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Repurposing Old Drugs for Alzheimer’s Treatment;Dispatches from the Land of Alzheimer's;2024-01-31
2. The Carnitine Palmitoyl-Transferase 2 Cascade Hypothesis for Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-01-16
3. Missing Puzzle Pieces in Dementia Research: HCN Channels and Theta Oscillations;Aging and disease;2024
4. ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer’s disease;Acta Neuropathologica Communications;2023-12-13
5. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model;Translational Neurodegeneration;2023-12-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3